Captrust Financial Advisors Editas Medicine, Inc. Transaction History

Captrust Financial Advisors

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$9.99 - $21.35 $6,933 - $14,816	-694 Reduced 29.7%	1,643 $19,000
Q2 2022 Aug 16, 2022	BUY	$9.99 - $21.35 $29 - $64	3 Added 0.13%	2,337 $28,000
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $83,677 - $164,205	-5,943 Reduced 71.8%	2,334 $44,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $516,105 - $788,640	-19,439 Reduced 70.14%	8,277 $220,000
Q3 2021 Nov 16, 2021	BUY	$39.27 - $72.94 $147,537 - $274,035	3,757 Added 15.68%	27,716 $1.14 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $20,620 - $37,325	659 Added 2.83%	23,959 $1.36 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $6,830 - $15,579	172 Added 0.74%	23,300 $979,000
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $184,292 - $574,254	6,808 Added 41.72%	23,128 $1.62 Million
Q3 2020 Nov 17, 2020	BUY	$28.06 - $37.16 $257,029 - $340,385	9,160 Added 127.93%	16,320 $460,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $50,320 - $93,404	-2,720 Reduced 27.53%	7,160 $221,000
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $27,602 - $60,806	1,855 Added 23.12%	9,880 $183,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $154,458 - $258,592	7,925 Added 7925.0%	8,025 $236,000
Q2 2019 Aug 13, 2019	SELL	$20.48 - $27.76 $34,385 - $46,609	-1,679 Reduced 94.38%	100 $2,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $32,622 - $44,342	1,679 Added 1679.0%	1,779 $43,000
Q4 2018 Feb 13, 2019	BUY	$18.19 - $31.79 $1,819 - $3,179	100 New	100 $2,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.